Table 5 Baseline characteristics of patients with biologic naïve or not.
From: Real-world retention rates of biologics in patients with rheumatoid arthritis
TCZ | Naïve | Second or later | p-value |
|---|---|---|---|
Cases (no.) | 18 | 66 | |
Age (years) | 63.1 ± 14.7 | 60.2 ± 15.5 | 0.4717 |
Male rate (%) | 27.8 | 18.2 | 0.5078 |
Body weight (kg) | 56.1 ± 11.7 | 55.3 ± 11.6 | 0.7902 |
BMI | 22.5 ± 4.2 | 22.6 ± 3.8 | 0.9510 |
ACPA positivity (%) | 100 | 97 | > 0.9999 |
RF positivity (%) | 100 | 86.4 | 0.1941 |
MMP3 (ng/ml) | 336.2 ± 361.6 | 325.5 ± 335.0 | 0.9061 |
PSL usage (%) | 66.7 | 60.6 | 0.7862 |
MTX usage (%) | 50 | 72.7 | 0.0890 |
PSL dose (mg/day) | 5.7 ± 2.4 | 5.1 ± 2.7 | 0.4377 |
MTX dose (mg/week) | 8.8 ± 3.6 | 8.5 ± 4.0 | 0.6741 |
